Vortioxetine in major depressive disorder : from mechanisms of action to clinical studies. An updated review
de Diego-Adeliño, Javier (Institut d'Investigació Biomèdica Sant Pau)
Crespo, José Manuel (Complejo Hospitalario Universitario de Ferrol)
Mora, Fernando (Hospital Universitario Infanta Leonor)
Neyra, Adrián (Hospital Universitario de Gran Canaria Dr. Negrín)
Iborra, Pedro (Hospital Universitario San Juan de Alicante)
Gutiérrez-Rojas, Luis (Hospital Universitario San Cecilio (Granada))
Salonia, Selman F. (Centro de Salud Mental de Jumilla)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Introduction: Vortioxetine is a multimodal-acting antidepressant that provides improvements on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has been found to be one of the most effective and best tolerated options for major depressive disorder (MDD) in head-to-head trials. Areas covered: The present review intends to gather the most relevant and pragmatic data of vortioxetine in MDD, specially focusing on new studies that emerged between 2015 and 2020. Expert opinion: Vortioxetine is the first antidepressant that has shown improvements both in depression and cognitive symptoms, due to the unique multimodal mechanism of action that combine the 5-HT reuptake inhibition with modulations of other key pre- and post-synaptic 5-HT receptors (agonism of 5-HT receptor, partial agonism of 5-HT receptor, and antagonism of 5-HT, 5-HT and 5-HT receptors). This new mechanism of action can explain the dose-dependent effect and can be responsible for its effects on cognitive functioning and improved tolerability profile. Potential analgesic and anti-inflammatory properties observed in preclinical studies as well as interesting efficacy and tolerability results of clinical studies with specific target groups render it a promising therapeutic option for patients with MDD and concomitant conditions (as menopause symptoms, pain, inflammation, apathy, sleep and/or metabolic abnormalities).
Grants:	Agència de Gestió d'Ajuts Universitaris i de Recerca PERIS SLT008/18/00207
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Antidepressant ; Cognition ; Efficacy ; Interactions ; Major depressive disorder ; Neurotransmission ; Pharmacology ; Safety ; Vortioxetine
Published in:	Expert Opinion on Drug Safety, Vol. 21 Núm. 5 (2022) , p. 673-690, ISSN 1744-764X

DOI: 10.1080/14740338.2022.2019705
PMID: 34964415

19 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles